US · Healthcare · Biotechnology
EPS came in at -0.24 against a street estimate of -0.24 — a beat of 0.0%.
Analysts rate Prime Medicine, Inc. Common Stock a strong buy (11 buy, 3 hold, 0 sell out of 14) with an average price target of $7.11.
| Fund | Stake |
|---|---|
| Alphabet Inc | 9.13% |
| BlackRock Inc | 5.29% |
| ARK Investment Management LLC | 4.60% |
| State Street Corp | 4.18% |
| T. Rowe Price Investment Management,Inc. | 2.89% |
| Vanguard Capital Management, LLC | 2.49% |
| Balyasny Asset Management LLC | 2.19% |
| The Goldman Sachs Group Inc | 1.89% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PRIME MEDICINE, INC. – FORM 10-Q SUMMARY For the Six Months Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $47.5 million in cash and cas | 2026-08-06 |
| Results announced · Q3 2026 PRIME MEDICINE Q2 2026 FINANCIAL RESULTS & BUSINESS SUMMARY HEADLINE NUMBERS • Cash position: $108.8 million in cash, cash equivalents, investments, | 2026-08-06 |
| Company announcement · Q3 2026 PRIME MEDICINE, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Prime Medicine, Inc. (NASDAQ: PRME) • Filing Date: July 6, 2026 • Headquarters: | 2026-07-08 |
| Shareholder vote results · Q2 2026 PRIME MEDICINE, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual meeting held June 5, 2026 with 140,384,724 shares represented out of 180,615,889 o | 2026-06-08 |
| Quarterly report · Q1 2026 PRIME MEDICINE, INC. — Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $64.1 million in cash and cash equivalents plus $71.4 | 2026-05-07 |
| Results announced · Q2 2026 PRIME MEDICINE Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $149.2 million in cash, cash equivalents, investments, and restri | 2026-05-07 |
| Proxy statement · Q4 2025 PRIME MEDICINE, INC. – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Michael Kelly and David Schenkein, M.D. as C | 2026-04-23 |
| Annual report FY2025 PRIME MEDICINE, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: Prime Medicine, Inc. (NASDAQ: PRME), Cambridge, MA-based biotec | 2026-03-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prime Medicine, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.